Esra GÜNDÜZ, Mehmet GÜNDÜZ, Levent BEDER, Noboru YAMANAKA, Kenji SHIMIZU, Hitoshi NAGATSUKA

p53 tümör baskılayıcı genin 72. Kodon polimorfizminin baş-boyun kanserlerindeki prognostik rolü

İnsan genom teknolojisindeki son zamanlardaki geliş-meler diğer kanserlerde olduğu gibi baş–boyun kanser-lerinde de birden fazla genin etkisi olduğunu göstermiş-tir. Bu konudaki yeni buluşlardan birisi de tek nükleotid polimorfizmlerinin kanser gelişimi ve prognozundaki rolüdür. p53 tümör baskılayıcı geni tüm kanser çeşitleri- nin oluşumunda rolü olduğu bilinen en önemli mole-küldür. Son zamanlarda p53 geninin 72. kodonunda tek nükleotid polimorfizmi bulunmuştur ve bu polimorfizmin kanser gelişim ve prognozundaki rolü araştırılmaktadır. Biz bu çalışmamızda 81 hastaya ait baş-boyun kanser örneğinde p53 geninin 72. kodonundaki bir polimorfizm ile klinik ve histopatolojik değişkenler arasındaki ilişkiyi inceledik. Sonuçlarımız, homo prolin alleli kodlayan hastalarda arginin alleli kodlayan hastalara göre, yüksek oranda ikinci kanser gelişimi ve düşük sağkalım süresi gibi daha kötü prognostik değişiklikler göstermiştir. Baş-ka genlerin tek nükleotid polimorfizm analizleri, bunların tek başına veya diğer tek nükleotid polimorfizmleri ile kıyaslanması, kanser gelişiminde daha iyi bilgiyi ve rutin kullanılabilecek moleküler biomarkırların bulunmasını sağlayacaktır.

The prognostic role of codon 72 polymorphism at p53 tumor supressor gene in head and neck cancer

Recent developments in human genome technology provided that multiple genes are involved in head and neck carcinogenesis as in other type of cancer. Another recent knowledge in this field is identification of single nucleotide polymorphisms (SNP) and their role in cancer development and prognosis. P53 tumor suppressor gene is the most well-known molecule, which has a role in almost every kind of cancer. A SNP located at codon 72 of p53 has recently been recognized and its role in cancer development and prognosis are questioned. In the current study, we examined codon 72 SNP of p53 in 81 head and neck cancer samples and compared the resultswith clinicopathological variables. Our results showed that loss of arginine allele was related with worse prognostic variables such as higher occurence of secondary cancer devolopment and worse disease-free and overall survivals. Analysis of SNPs for other genes and comparison with alone or other SNPs will supply better knowledge and identification of routine molecular biomarkers for cancer progress.

PDF

___

1. Renan MJ. How many mutations are required for tumorigenesis? Implications from human cancer data. Mol Carcinog 1993;7: 139-46.
2. Harari PM, Wheeler DL, Grandis JR. Molecular target approaches in head and neck cancer: epidermal growth factor receptor and beyond. Semin Radiat Oncol 2009;19: 63-8.
3. Knudson AG. Antioncogenes and human cancer.Proc Natl Acad Sci USA 1993;90: 10914-21.
4. Gunduz M, Gunduz E, Rivera RS, Nagatsuka H. The inhibitor of growth (ING) gene family: potential role in cancer therapy. Curr Cancer Drug Targets 2008;8: 275-84.
5. Gunduz M, Nagatsuka H, Demircan K, Gunduz E, Cengiz B, Ouchida M, et al. Frequent deletion and down-regulation of ING4, a candidate tumor suppressor gene at 12p13, in head and neck squamous cell carcinomas. Gene 2005;356: 109-17.
6. Gunduz M, Ouchida M, Fukushima K, Ito S, Jitsumori Y, Nakashima T, et al. Allelic loss and reduced expression of the ING3, a candidate tumor suppressor gene at 7q31, in human head and neck cancers. Oncogene 2002;21: 4462-70.
7. Gunduz M, Ouchida M, Fukushima K, Hanafusa H, Etani T, Nishioka S, et al. Genomic structure of the human ING1 gene and tumor-specific mutations detected in head and neck squamous cell carcinomas. Cancer Res 2000;60: 3143-6.
8. Wood NB, Kotelnikov V, Caldarelli DD, Hutchinson J, Panje WR, Hegde P, et al. Mutation of p53 in squamous cell cancer of the head and neck: relationship to tumor cell prolifera. Laryngoscope 1997;107: 827-33.
9. Gupta VK, Schmidt AP, Pashia ME, Sunwoo JB, Scholnick SB.Multiple regions of deletion on chromosome arm 13q in head-and-neck squamous-cell carcinoma. Int J Cancer 1999;84: 453-7.
10. Gold KA, Kim ES. Role of molecular markers and gene profiling in head and neck cancers. Curr Opin Oncol 2009;21: 206-11.
11. Werbrouck J, De Ruyck K, Duprez F, Van Eijkeren M, Rietzschel E, Bekaert S, et al. Single-nucleotide polymorphisms in DNA double-strand break repair genes: association with head and neck cancer and interaction with tobacco use and alcohol consumption. Mutat Res 2008;656: 74-81.
12. Imyanitov EN. Gene polymorphisms, apoptotic capacity and cancer risk. Hum Genet 2009;125: 239-46.
13. Hiyama T, Yoshihara M, Tanaka S, Chayama K. Genetic polymorphisms and head and neck cancer risk. Int J Oncol 2008;32: 945-73.
14. Kiuru A, Servomaa K, Grénman R, Pulkkinen J, Rytömaa T. p53 mutations in human head and neck cancer cell lines. Acta Otolaryngol Suppl1997;529: 237-40.
15. Shen H, Zheng Y, Sturgis EM, Spitz MR, Wei Q. p53 codon 72 polymorphism and risk of squamous cell carcinoma of the head and neck: a case-control study. Cancer Lett 2002;183: 123-30.
16. Ji X, Neumann AS, Sturgis EM, Adler-Storthz K, Dahlstrom KR, Schiller JT, et al. p53 codon 72 polymorphism associated with risk of human papillomavirus-associated squamous cell carcinoma of the oropharynx in never-smokers. Carcinogenesis 2008;29: 875-9.
17. Brant O, Hoffmann M, Kanappilly A, Görögh T, Gottschlich S. p53 codon 72 polymorphism in squamous cell carcinoma of the head and neck region. Anticancer Res 2007;27: 3301-5.
18. Overdevest JB, Theodorescu D, Lee JK. Utilizing the molecular gateway: the path to personalized cancer management. Clin Chem 2009;55: 684-97.
19. Huang RS, Ratain MJ. Pharmacogenetics and pharmacogenomics of anticancer agents. CA Cancer J Clin 2009;59: 42-55.
20. Xu Y, Yao L, Zhao A, Quyang T, Li J, Wang T, et al. Effect of p53 codon 72 genotype on breast cancer survival depends on p53 gene status. Int J Cancer 2008;122: 2761-6.